National Biocontainment Laboratory (NBL)

德克萨斯大学医学部提议建造一个174,233平方米的建筑。英国《金融时报》最先进的国家生物遏制实验室(NBL)，旨在提供灵活、高水平的生物遏制设施，支持拟议的第六地区生物防御和新发传染病研究英才中心(第六地区RCE)和其他参与执行NIAID生物防御研究议程的RCE的研究活动。利用UTMB在生物防御研究方面独特的广度和深度，NBL将提供必要的实验室基础设施，以实现NIAID通过以下方式加强国家安全的目标 为A-C类选定药物开发改进的诊断、治疗和疫苗对策。具体目标是：(1)为涉及需要BSL-3/4容器的制剂的研究建立一个安全的实验室环境，为调查人员提供最大限度的安全，并提供多余的保障措施，防止感染剂释放到社区；(2)通过提供先进的生物分子成像仪器和随时获得尖端蛋白质组和基因组学核心设施，促进这项研究；(3)为国家生物防御努力生产急需的诊断和研究试剂；(4)为培训熟练掌握BSL-3/4实验室调查的新一代调查人员和支持人员提供框架；(5)提供BSL-3临床隔离能力，支持1/2期临床试验和对接触传染病病原体的人员进行管理；以及(6)在发生国家生物紧急情况时提供有效的突击实验室和技术能力。这些NBL活动将由 促进其作为国家生物防御研究网络的一部分的行政机构。

The University of Texas Medical Branch proposes construction of a 174,233 sq. ft. state-of-the-art National Biocontainment Laboratory (NBL) designed to provide flexible, high level biocontainment facilities supporting the research activities of the proposed Region VI Center of Excellence for Biodefense and Emerging Infectious Diseases Research (Region VI RCE) and other RCE's engaged in executing NIAID's biodefense research agenda. Drawing on the unique breadth and depth of UTMB's faculty in biodefense research, the NBL will provide the laboratory infrastructure necessary to achieve NIAID's objective of enhancing national security by developing improved diagnostic, therapeutic and vaccine countermeasures for category A-C select agents. Specific objectives are: (1) to establish a secure laboratory environment for research involving agents requiring BSL-3/4 containment, providing maximal safety for investigators and redundant safeguards preventing release of infectious agents into the community; (2) to facilitate this research by providing sophisticated instrumentation for biomolecular imaging and ready access to cutting-edge proteomics and genomics core facilities; (3) to produce critically needed diagnostic and research reagents for the national biodefense effort; (4) to provide a framework for the training of a new generation of investigators and support personnel skilled in BSL-3/4 laboratory investigation; (5) to provide BSL-3 clinical isolation capabilities supporting phase 1/2 clinical trials and management of persons exposed to infectious agents, and (6) to provide effective surge laboratory and technical capacity in the event of a national biological emergency. These NBL activities will be supported by an administrative structure facilitating its role as part of a national biodefense research network.